Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes

ISSN： 1744-6651

Source： Expert Review of Endocrinology and Metabolism, Vol.8, Iss.3, 2013-05, pp. : 229-238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GLP-1 receptor agonists in the treatment of Type 2 diabetes

By Ahrén Bo

Diabetes Management, Vol. 3, Iss. 5, 2013-09 ,pp. : 401-413

Future Medicine

Access to resources Recommend Favorite

Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes

Current Diabetes Reviews, Vol. 6, Iss. 4, 2010-07 ,pp. : 191-200

Bentham Science Publishers

Access to resources Recommend Favorite

Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes

Current Diabetes Reviews, Vol. 3, Iss. 1, 2007-01 ,pp. : 15-23

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Safety of Long-Acting β 2 -Agonist and Inhaled Corticosteroid Combination Therapy in COPD

By Decramer Marc Ferguson Gary

COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 3, Iss. 3, 2006-09 ,pp. : 163-171

Informa Healthcare

Access to resources Recommend Favorite

Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes

Current Diabetes Reviews, Vol. 7, Iss. 1, 2011-01 ,pp. : 61-74

Bentham Science Publishers

Access to resources Recommend Favorite